




Introducing the CUSTOMFLEX® ARTIFICIALIRIS

A CUSTOM-MADE IMPLANT TO TREAT
ANIRIDIA OR OTHER IRIS DEFECTS



The CUSTOMFLEX® ARTIFICIALIRIS is a foldable iris prosthesis custom-made for each individual patient, replicating the natural appearance of the patient's eye. The CUSTOMFLEX® ARTIFICIALIRIS is the first and only FDA approved device for treating full or partial aniridia or other iris defects in adults and children.

PROVEN SCIENCE MEETS EXPERT CRAFTSMANSHIP

OVERVIEW

The CUSTOMFLEX® ARTIFICIALIRIS is intended for use as an iris prosthesis for the treatment of iris defects. The CUSTOMFLEX® ARTIFICIALIRIS is indicated for use in children and adults for the treatment of full or partial aniridia resulting from congenital aniridia, acquired defects, or other conditions associated with full or partial aniridia. When implanted, the CUSTOMFLEX® ARTIFICIALIRIS mimics the natural iris and produces an improvement in the visual symptoms associated with aniridia that most affect the patient's quality of life.

These symptoms include:

- Light sensitivity day and night
- Reading difficulty
- Difficulty night driving
- Starbursts
- Glare and halos day and night

CUSTOM-COLOR MATCH

Every CUSTOMFLEX® ARTIFICIALIRIS is custom-made to match the patient's natural iris tissue, addressing both symptomatic and cosmetic aspects of iris defects.




Photo courtesy of Michael Snyder, M.D.
Cincinnati Eye Institute

Left eye had the CUSTOMFLEX® ARTIFICIALIRIS implanted after traumatic injury.

INDICATIONS

CONGENITAL ANIRIDIA



Photos courtesy of Michael Snyder, M.D.
Cincinnati Eye Institute

Before implantation of the
CUSTOMFLEX® ARTIFICIALIRIS



After implantation of the
CUSTOMFLEX® ARTIFICIALIRIS




Photos courtesy of Michael Snyder, M.D.
Cincinnati Eye Institute

Before implantation of the
CUSTOMFLEX® ARTIFICIALIRIS




After implantation of the
CUSTOMFLEX® ARTIFICIALIRIS

TRAUMATIC INJURY




Photos courtesy of Kevin M. Miller, M.D.
Jules Stein Eye Institute

Photo of contralateral eye used
as template for manufacture of
the **CUSTOMFLEX®**
ARTIFICIALIRIS




Before implantation of the
CUSTOMFLEX® ARTIFICIALIRIS




After implantation of the
CUSTOMFLEX® ARTIFICIALIRIS

OCULOCUTANEOUS ALBINISM



Photos courtesy of Michael Snyder, M.D.
Cincinnati Eye Institute

Before implantation of the
CUSTOMFLEX® ARTIFICIALIRIS



After implantation of the
CUSTOMFLEX® ARTIFICIALIRIS

CLINICAL SCIENCE

The safety and efficacy of the CUSTOMFLEX® ARTIFICIALIRIS was demonstrated in a non-randomized clinical trial of 447 eyes of 389 adult and pediatric patients with aniridia or other iris defects.

BENEFITS:

- There was a decrease in the severity of day-time symptoms of light sensitivity, glare and halos
- There was a decrease in the severity of night-time symptoms of light sensitivity, glare, halos and starbursts
- Reading was improved
- Difficulty driving at night was improved
- There was a three-fold improvement in the patients' ability to complete normal vision-related activities of daily living, as measured by a standardized health related quality of life questionnaire.
- Satisfaction with the cosmetic appearance was high, with 93.8% of patients rating their appearance as improved to very much improved after implantation of the CUSTOMFLEX® ARTIFICIALIRIS.
- Although the CUSTOMFLEX® ARTIFICIALIRIS is not designed to improve vision, 67.2% of the eyes had better uncorrected visual acuity (vision without glasses or contact lenses) after the artificial iris surgery; and, 27.7% of the eyes had uncorrected vision that was unchanged.

RISKS:

- None of the eyes had a clinically significant loss of more than 2 lines on the eye chart of best corrected vision at 12 months postoperatively that was caused by the CUSTOMFLEX® ARTIFICIALIRIS.
- Increases in intraocular pressure greater than 30 mm Hg were the most common adverse event reported in the study.
- The CUSTOMFLEX® ARTIFICIALIRIS implant remained in its intended position in the majority of eyes throughout the 12 month study; secondary surgeries could be performed when needed to reposition the device.
- Inflammation occurring at one month or later after surgery was related to the CUSTOMFLEX® ARTIFICIALIRIS device in 0.7% of the eyes.

Contraindications: CUSTOMFLEX® ARTIFICIALIRIS is contraindicated for patients with certain eye conditions, such as uncontrolled inflammation, severe chronic uveitis, microphthalmus, untreated retinal detachment, untreated chronic glaucoma, rubella cataract, rubeosis of the iris, proliferative diabetic retinopathy, Stargardt's retinopathy, or intraocular infections, or in pregnant women.

Warning: Implantation of the CUSTOMFLEX® ARTIFICIALIRIS is not recommended in children who are less than 3 years of age because their eyes are still in a stage of major growth development that would be disrupted by ocular surgery.

Refer to the Patient Information Brochure for complete study results, other warnings, precautions, and instructions for the use of the device. www.veo-ophthalmics.com

LEARN MORE ABOUT THE CUSTOMFLEX® ARTIFICIALIRIS

To learn more about the CUSTOMFLEX® ARTIFICIALIRIS, please visit www.veo-ophthalmics.com. Please contact us at 513-872-1330 or info@veo-ophthalmics.com to find a certified surgeon in your area.

ON OUR WEBSITE, WE OFFER:

- Product Information
- Patient Information
- Publication Lists

The CUSTOMFLEX® ARTIFICIALIRIS was developed, and is manufactured by, HumanOptics AG (Dr. Schmidt Intraocularlinsen) in collaboration with Professor H.R. Koch (Bonn, Germany).

The clinical trial is posted on [clinicaltrials.gov](https://www.clinicaltrials.gov).
<https://www.clinicaltrials.gov/ct2/show/NCT01860612?term=NCT01860612&rank=1>



Distributed by:
VEO Ophthalmics
3308 Jefferson Ave, Upper Level
Cincinnati, OH 45220
(513) 872-1330

